Interleukin-1 as a possible agent for treatment of infection.
Treatment of experimental animals with bacterial products, such as cell wall components of gram-negative bacteria, leads to enhanced resistance to a variety of microorganisms. Since interleukin-1 and other pro-inflammatory cytokines are induced by such bacterial products, it has been investigated whether these cytokines are also capable of enforcing host resistance. It has been possible to demonstrate that a low dose of interleukin-1 protects mice against death from either gram-negative or gram-positive bacteria, Candida albicans and Plasmodium berghei. The protection against lethal bacterial and fungal infection can be produced in both normal and neutropenic animals. Despite extensive investigations, the mechanism of protection is not understood. A possible mechanism, which is currently being investigated, is that interleukin-1 interferes with the deleterious action of the pro-inflammatory cytokines during the lethal phase of the infection.
van der Meer
J W
JW
Department of Internal Medicine, University Hospital Nijmegen, The Netherlands.
Vogels
M
M
Curfs
J H
JH
Eling
W M
WM
D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy* / Q000276:immunology; D002177:Candidiasis / Q000188:drug therapy / Q000276:immunology; D016207:Cytokines / Q000502:physiology; D007113:Immunity, Innate; D007155:Immunologic Factors / Q000502:physiology; D007239:Infections / Q000276:immunology; D007375:Interleukin-1 / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D008288:Malaria / Q000188:drug therapy / Q000276:immunology; D010587:Phagocytosis / Q000187:drug effects
D016207:Cytokines; D007155:Immunologic Factors; D007375:Interleukin-1